Navigation Links
Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test
Date:11/28/2012

m Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty of finding a suitable successor chief executive officer; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conju
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Saddleback Memorial Named First Robotic Training Epicenter for Gynecologic Surgery in Orange County
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
5. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
6. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
7. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
8. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
9. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
11. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- An intensive effort to sterilize ... animal shelter in Florida and euthanized, a new study reveals. ... to slow their intake into animal control," Dr. Julie Levy, ... College of Veterinary Medicine, said in a university news release. ... making a big impact," she explained, "so we wanted to ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
(Date:8/22/2014)... again attained the distinguished Magnet hospital designation by ... Program. Considered the gold standard for nursing excellence, ... and professionalism. It is the top international credential ... redesignate Newport Hospital was based on the hospital,s ... practice. , "It is a privilege for us ...
(Date:8/22/2014)... (HealthDay News) -- People who use reduced-nicotine cigarettes don,t ... of nicotine, according to a new study. This ... smokers, the researchers say. The month-long study included ... regular cigarettes with nicotine emission levels of 1.2 milligrams ... to reduced-nicotine cigarettes for the next three weeks. ...
Breaking Medicine News(10 mins):Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Neutering Project Curbed Feral Cat Population 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... chief Commissioner Lester Crawford prevented two senior officials// from deciding ... which is a 'morning after' pill. ,These statements ... for Reproductive Rights. Dr. Steven Galson, director of the FDA's ... thing of approving the action to sell Plan B as ...
... The Schizophrenia Fellowship was announced by the greater Southern Area ... family who are unable to support// patients affected with the ... family sensitive mental health program. It would receive about $2 ... Dr Murray Wright, a director of clinical operations mental health, ...
... Women's Hospital (RBWH), Sydney struggles with an outbreak of ... were found with a bacterium called carbapenem ... ,To prevent the spread, 12 patients from burns unit ... shifted to Sydney hospital and some to Brisbane's Princess ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... of commonly used cholesterol-lowering drugs, used by patients ... anti-arrhythmic effect. Scientists with the ... committee evaluated about 458 sudden cardiac deaths with ... of Statin therapy. Among these about, 229 patients ...
... who tried just one cigarette are twice as likely as those ... 3 years it was proved true by another study. ... children trying even one cigarette. In a study with 2000 teens, ... 15-year olds have smoked a cigarette. From about 36 London schools ...
Cached Medicine News:
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: